MRTX1719 Clinical Trials (2026): 2 Studies for Solid Tumor & Advanced Solid Tumor
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 MRTX1719 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Solid Tumor & Advanced Solid Tumor) and 372 total planned enrollment. 2 MRTX1719 clinical trials are actively recruiting at 22 U.S. sites across 12 states. Most recent activity: NCT07382544 (Jan 2032).
Where to Participate: All MRTX1719 Trial Sites in the U.S. (22 sites across 12 states)
Every actively recruiting MRTX1719trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Mayo Clinic | Phoenix85054-4502 | NCT05245500 | Map |
| CO | Sarah Cannon Research Institute (SCRI) - HealthONE Location | Denver80218-1238 | NCT05245500 | Map |
| CO | Rocky Mountain Cancer Centers, LLP - Oncology | Lone Tree80124 | NCT05245500 | Map |
| FL | Mayo Clinic | Jacksonville32224 | NCT05245500 | Map |
| FL | Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando32827 | NCT05245500 | Map |
| MA | Dana-Farber Cancer Institute | Brookline02251 | NCT05245500 | Map |
| MI | Cancer and Hematology Centers of Western Michigan | Norton Shores49444 | NCT05245500 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT05245500 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT05245500 | Map |
| NY | David H Koch, Memorial Sloan Kettering Cancer Center | New York10021 | NCT05245500 | Map |
| NY | New york cancer and blood specialists - Oncology | Port Jefferson Station11776 | NCT05245500 | Map |
| NY | New york cancer and blood specialists - Oncology | Port Jefferson Station11776 | NCT05245500 | Map |
| NC | University of North Carolina | Chapel Hill27599 | NCT05245500 | Map |
| NC | University of North Carolina - Gastroenterology and Hepatology | Chapel Hill27599 | NCT05245500 | Map |
| TN | Vanderbilt - Ingram Cancer Center | Nashville37232-5505 | NCT05245500 | Map |
| TX | Ut Southwestern | Dallas75235 | NCT05245500 | Map |
| TX | Texas Oncology - DFW | Fort Worth76104 | NCT05245500 | Map |
| TX | MDACC | Houston77030 | NCT05245500 | Map |
| TX | The University of Texas M. D. Anderson Cancer Center | Houston77030 | NCT07382544 | Map |
| TX | South Texas Accelerated Research Therapeutics | San Antonio78229 | NCT05245500 | Map |
| TX | Texas Oncology, P.A. - Oncology | Tyler78503 | NCT05245500 | Map |
| VA | Virginia Cancer Specialists, PC | Fairfax22031 | NCT05245500 | Map |
MRTX1719 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 2 | 2 |
Recruiting MRTX1719 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07382544 | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | P1 | Advanced Cancer | 36 | Feb 2026 |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | P1 | Mesothelioma | 336 | Jun 2022 |
MRTX1719 clinical trials by indication
Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07382544 | — | P1 | recruiting | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss |
Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05245500 | — | P1 | recruiting | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion |
All MRTX1719 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07382544 | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | P1 | recruiting | 36 | M.D. Anderson Cancer Center | Feb 2026 | |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | P1 | recruiting | 336 | Bristol-Myers Squibb | Jun 2022 |
MRTX1719 clinical trials: frequently asked questions
- How many MRTX1719 clinical trials are there?
- 2 MRTX1719 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are MRTX1719 clinical trials recruiting in 2026?
- Yes — 2 MRTX1719 trials are actively recruiting in 2026, with 22 U.S. sites across 12 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is MRTX1719 being studied for?
- MRTX1719 is being studied for Solid Tumor, Advanced Solid Tumor, Malignant Peripheral Nerve Sheath Tumors, Advanced Cancer, Non Small Cell Lung Cancer and 2 more. The trials are grouped by indication on this page.
- What phase is MRTX1719 in?
- MRTX1719 clinical trials span 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors MRTX1719 clinical trials?
- The lead sponsor across the most MRTX1719 trials is Bristol-Myers Squibb, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MRTX1719as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: